Your global partner for specialty and rare therapies
The Problem We Solve
Market failure of scientifically viable therapies due to commercial missteps.
Traditional commercialization is a mismatch for rare disease
Critical resources gaps along the development journey
Cash runways cannot withstand inevitable clinical setbacks
Declining IPO rates require a broader range of end-states
The Actum Solution
A flexible operating partner model to enable complex commercialization.
Purpose-built for rare, orphan, and complex conditions
Ideal for founder-led, clinical-stage biopharma companies
Phase 2 planning prevents early commercial missteps
International capabilities enabling global perspective
Go-to-market optionality (i.e., non-dilutive funding, in-licensing support, milestone-based)
Who We Work With
BIOPHARMA C-SUITE LEADERS
We work with biopharma leaders who are looking to strengthen and reinforce asset value across all stages of the product lifecycle – prelaunch through mature therapies. Our primary relationships are typically with C-suite leaders with broad purview over their organization, looking to reinforce and strengthen their plans and teams on the road to creating value.
Chief Executive Officer
Chief Financial Officer
Chief Operating Officer
Chief Commercial Officer
BIOPHARMA FUNCTIONAL BUSINESS LEADERS
Once we complete our Actum Comprehensive Corporate Diagnosis, our team of experts is prepared to seamlessly integrate to support your functional business leads as needed, including:
Finance
Market Access
Operations
Communications
Sales and Marketing
INVESTORS
Actum also works directly with the investor community, strengthening due diligence efforts with our comprehensive Actum Comprehensive Corporate Diagnosis as well as matching high-potential biopharma companies with investment partners.
Managing Partner
Venture Partner
Operating Partner
Principal